

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Paris et al. Confirmation No.: 7571
Serial No.: 10/780,905 Art Unit: 1654
Filed: February 18, 2004 Examiner: Cordero Garcia, Marcela M.
For: ANTI-ANGIOGENIC AND ANTI- Attorney Docket No.: 12062-105006
TUMORAL PROPERTIES OF (RSK006)
BETA AND GAMMA SECRETASE
INHIBITORS

Mail Stop: RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL OF SEQUENCE LISTING UNDER 37 C.F.R. § 1.821

Sir:


Applicants, in connection with the above identified patent application, submit herewith a Substitute Sequence Listing in paper and computer readable form pursuant to 37 C.F.R. §§ 1.821(c) and (e).

Pursuant to 37 C.F.R. §§ 1.821(f) and (g), I hereby state that the content of the sequence listing information recorded in the computer readable form is identical to the written (paper) Sequence Listing and includes no new matter.

Applicants respectfully request entry of this submission into the file history of the subject application. No fees are believed due in connection with the filing of this transmittal. However, if it is determined that an additional fee is due, please charge the required fee to King & Spalding Deposit Account No. 50-3732.

Date: October 23, 2007

Respectfully submitted,



Richard M. Enmon, Jr. 52,865
KING & SPALDING (Reg. No.)
1185 Avenue of the Americas
New York, New York 10036
(212) 556-2100